Clinical factors for predicting cardiovascular risk, need for renal replacement therapy, and mortality in patients with non–dialysis-dependent stage 3–5 chronic kidney disease from...

por Filipa Alexandre, Ana, Stoelzel, Matthias, Kiran, Amit, Garcia-Hernandez, Alberto, Morga, Antonia, Kalra, Philip A.
Publicado 2023

Population pharmacokinetics and pharmacodynamics of a novel vascular adhesion protein-1 inhibitor using a multiple-target mediated drug disposition model

por Snelder, Nelleke, Hoefman, Sven, Garcia-Hernandez, Alberto, Onkels, Hartmut, Larsson, Tobias E., Bergmann, Kirsten R.
Publicado 2020

Mechanism-based modeling of the effect of a novel inhibitor of vascular adhesion protein-1 on albuminuria and renal function markers in patients with diabetic kidney disease

por Hoefman, Sven, Snelder, Nelleke, van Noort, Martijn, Garcia-Hernandez, Alberto, Onkels, Hartmut, Larsson, Tobias E., Bergmann, Kirsten R.
Publicado 2020

Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults

por Kusawake, Tomohiro, den Adel, Martin, Groenendaal-van de Meent, Dorien, Garcia-Hernandez, Alberto, Takada, Akitsugu, Kato, Kota, Ohtsu, Yoshiaki, Katashima, Masataka
Publicado 2017

Transcultural adaptation and validation of the Spanish language version of the questionnaire OQLQ for the assessment of quality of life in orthognathic patients

por Sánchez-Burgos, Rocío, Martínez-Gimeno, Carlos, Arribas-García, Ignacio, Gómez-Oliveira, Guillermo, Álvarez-Florez, Modesto, García-Hernández, Alberto, Martínez-Martínez, Ricardo
Publicado 2018

Primary outcomes of the VIDI study: phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edema

por Nguyen, Quan Dong, Sepah, Yasir J., Berger, Brian, Brown, David, Do, Diana V., Garcia-Hernandez, Alberto, Patel, Sunil, Rahhal, Firas M., Shildkrot, Yevgeniy, Renfurm, Ronny W.
Publicado 2019

RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrom...

por Steg, Ph. Gabriel, Mehta, Shamir R., Jukema, J. Wouter, Lip, Gregory Y.H., Gibson, C. Michael, Kovar, Frantisek, Kala, Petr, Garcia-Hernandez, Alberto, Renfurm, Ronny W., Granger, Christopher B.
Publicado 2011

Prognostic imaging biomarkers for diabetic kidney disease (iBEAt): study protocol

por Gooding, Kim M., Lienczewski, Chrysta, Papale, Massimo, Koivuviita, Niina, Maziarz, Marlena, Dutius Andersson, Anna-Maria, Sharma, Kanishka, Pontrelli, Paola, Garcia Hernandez, Alberto, Bailey, Julie, Tobin, Kay, Saunavaara, Virva, Zetterqvist, Anna, Shelley, David, Teh, Irvin, Ball, Claire, Puppala, Sapna, Ibberson, Mark, Karihaloo, Anil, Metsärinne, Kaj, Banks, Rosamonde E., Gilmour, Peter S., Mansfield, Michael, Gilchrist, Mark, de Zeeuw, Dick, Heerspink, Hiddo J. L., Nuutila, Pirjo, Kretzler, Matthias, Welberry Smith, Matthew, Gesualdo, Loreto, Andress, Dennis, Grenier, Nicolas, Shore, Angela C., Gomez, Maria F., Sourbron, Steven
Publicado 2020